Pfizer, Inc.(PFE) - Stock detail

Pfizer, Inc.

US
PFE
Pfizer Inc.(Listing date: 01/17/1944)

Pfizer Inc. was incorporated under the laws of Delaware on June 2, 1942. It is a research-based global biopharmaceutical company. Using science and global resources, the company brings therapies that extend and significantly improve people's lives through the discovery, development, manufacturing and distribution of healthcare products, including innovative medicines and vaccines. The company operates in both developed and emerging markets, committed to advancing health, prevention, treatment and cure for the world's most feared diseases of our time. It collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare services worldwide.

🎯 Pfizer, Inc. (PFE) 💰 Analysis Report 📅 Generated: 2026-06-11 17:46:59 ET

Investment Analysis: Pfizer, Inc. (PFE)

Investment Recommendation: HOLD

Target Price: $27.50 (Expected increase of approximately 5.1% from current price of $26.17)

Confidence Level: 0.65

Risk Score: 0.55 (Moderate Risk)

Detailed Reasoning:

1. Technical Analysis Synthesis

The technical indicators present a mixed but cautiously optimistic picture:

  • Bullish Signals: Price ($26.17) has closed above all short-term moving averages (5, 10, 20-day SMAs and EMAs). The MACD has shown a bullish crossover with histogram turning positive. The strong volume-supported bullish candle on June 11th suggests accumulation.
  • Resistance Concerns: Immediate resistance at the 60-day SMA ($26.59) and Bollinger Band upper limit ($26.33) creates a confluence zone. A decisive break above $26.60 is needed to confirm trend reversal.
  • Trend Strength: The extremely low ADX (8.52) indicates a weak, directionless market, making false signals more likely.

2. Fundamental Valuation Assessment

  • Current Valuation: At $26.17, PFE trades at a P/E of 19.48 (TTM), which is slightly above historical pharmaceutical averages but reasonable given the company’s market position.
  • Financial Health: Mixed fundamentals with declining revenue (-1.65% YoY for FY2025) and net income (-3.24%), but strong gross margins (74.33%) and adequate liquidity (current ratio 1.16).
  • Fair Value Range: Based on earnings multiples and recent trading patterns, a reasonable near-term range is $24.00-$29.00.

3. Catalyst Analysis

  • Positive Catalysts: RBC upgrade to “Sector Perform” reduces institutional selling pressure. FDA pediatric approval for HYMPAVZI demonstrates pipeline execution. The $25B Seagen acquisition provides oncology growth platform.
  • Negative Pressures: High dividend yield (6.7%) raises sustainability concerns amid declining cash flows. Competitive disadvantages in obesity drug market. Debt from acquisitions (58.31% debt-to-asset ratio).

4. Risk-Reward Assessment

The current price offers a balanced risk-reward profile:

  • Upside Potential: Successful breakout above $26.60 could target $27.50-$28.00 range. Seagen integration success and pipeline catalysts could drive multiple expansion.
  • Downside Risk: Failure to break resistance could see retracement to $25.00-$25.45 support zone. Dividend sustainability concerns could pressure the stock if cash flow deteriorates further.

5. Target Price Justification

The $27.50 target price is derived from:

  • Technical Perspective: Next resistance level after breaking $26.60 confluence zone, aligning with early April support-turned-resistance.
  • Valuation Basis: Applying a 20x P/E multiple to TTM EPS of $1.36 yields $27.20, rounded to $27.50 for technical alignment.
  • Sentiment Adjustment: Incorporating modest multiple expansion potential if near-term catalysts materialize, while acknowledging ongoing fundamental challenges.

Strategic Rationale for HOLD Recommendation: Existing shareholders should maintain positions given the improving technical setup and reduced downside risk signaled by the RBC upgrade. The high dividend yield provides income support while waiting for pipeline catalysts. However, new buyers should wait for a confirmed breakout above $26.60 before establishing positions, as the immediate resistance presents a significant hurdle. The moderate confidence level reflects the tension between improving technicals and persistent fundamental challenges in Pfizer’s transition phase. ✅ Analysis Complete